Current epidemiology of chronic liver disease
Authors:
Open Access
- 22 December 2023
- journal article
- review article
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 12, goae069
Abstract
Chronic liver disease presents a significant global health burden, characterized by several etiologies, including metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), chronic hepatitis B virus infection, and chronic hepatitis C virus infection. This review explored current epidemiological trends and projections for each etiology, looking into their respective burdens and challenges. MASLD, formerly known as nonalcoholic fatty liver disease, is the most prevalent cause of chronic liver disease, and its global incidence and prevalence are steadily rising. ALD, fueled by increased alcohol consumption, is also on the rise, with concerning implications for future mortality rates. Chronic hepatitis B and C infections remain major public health concerns, particularly in specific regions of the world, necessitating concerted efforts for screening and treatment. The coronavirus disease 2019 (COVID-19) pandemic has impacted the epidemiology of chronic liver disease, exacerbating mortality rates and disrupting healthcare services. Mental health issues arising from the pandemic further complicate the treatment of chronic liver disease, making comprehensive healthcare strategies essential. Despite advancements in treatment, chronic liver disease continues to impose a substantial economic burden, emphasizing the importance of preventive measures and early intervention. In conclusion, ongoing surveillance and research efforts are crucial for understanding and addressing the evolving landscape of chronic liver disease. Comprehensive strategies that encompass prevention, screening, and treatment of its different etiologies are essential for mitigating its impact and improving patient outcomes.Keywords
This publication has 68 references indexed in Scilit:
- Prospective clinical trials and novel therapies in the medical management of severe alcohol‐associated hepatitisClinical Liver Disease, 2022
- 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2022
- Geographical similarity and differences in the burden and genetic predisposition of NAFLDHepatology, 2022
- Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center StudyClinical Gastroenterology and Hepatology, 2021
- Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018Clinical Gastroenterology and Hepatology, 2021
- Epidemiology of Hepatocellular CarcinomaHepatology, 2020
- Trends in the Burden of Chronic Liver Disease Among Hospitalized US AdultsJAMA Network Open, 2020
- Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness AnalysisPharmacoEconomics, 2019
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesHepatology, 2012